NASDAQ issues deficiency letter to Commonwealth Biotechnologies, grants grace period upto March 15, 2010

Commonwealth Biotechnologies, Inc. (“CBI” or “Company”)) (NASDAQ Capital Market:CBTE) today announced that on September 15, 2009, CBI received a letter from The NASDAQ Stock Market indicating that the bid price of the Company’s common stock had closed below the minimum $1.00 per share threshold set forth in NASDAQ Listing Rule 5550(a)(2) for the prior 30 consecutive business days. As such NASDAQ has granted the Company 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement. Should the Company satisfy the criteria for initial listing on The NASDAQ Capital Market (except for bid price) as of March 15, 2010, the Company will be entitled to a second 180-calendar day period, through September 13, 2010, to regain compliance with the minimum bid price requirement. CBI will regain compliance with NASDAQ’s minimum bid price requirement if the bid price of its common stock closes at $1.00 or higher for a minimum of ten consecutive business days during the compliance period. This most recent notice has no impact on the Company’s listing at this time.

Source: Commonwealth Biotechnologies, Inc.

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.